Ignite Creation Date:
2024-05-06 @ 4:24 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04979910
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2021-07-19
Brief Title:
Targeting IL-17A for Treatment-Resistant Depression
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The proposed study aims to test ixekizumab a monoclonal antibody mAb against interleukin 17A IL-17A in patients with treatment-resistant depression TRD
Detailed Description:
In the proposed study n20 adult individuals with TRD will be treated with ixekizumab for 4 weeks Participants will complete screening procedures body fluid analyses and brain imaging before and after treatment with ixekizumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None